International Journal of General Medicine,
Год журнала:
2024,
Номер
Volume 17, С. 6009 - 6027
Опубликована: Дек. 1, 2024
Hepatocellular
carcinoma
(HCC)
triggered
by
Hepatitis
B
virus
(HBV)
remains
a
significant
clinical
challenge,
necessitating
novel
therapeutic
interventions.
Copper
ionophores,
recognized
for
introducing
an
innovative
type
of
programmed
cell
death
termed
cuproptosis,
present
promising
potentials
cancer
therapy.
Nevertheless,
The
role
cuproptosis-related
lncRNAs
(CRLRs)
in
HBV-HCC
has
not
been
clearly
elucidated.
This
study
utilised
univariate
Cox,
least
absolute
shrinkage
and
selection
operator
(LASSO),
multivariable
Cox
regression
analyses
to
establish
signature
CRLRs
HBV-HCC.
prognostic
model
was
validated
with
independent
internal
validation
cohort,
combined
parameters,
used
construct
nomogram
patient
survival
predictions.
Gene
Ontology
(GO)
Set
Enrichment
Analysis
(GSEA)
were
employed
explore
associated
biological
pathways.
Additionally,
protein-protein
interaction
(PPI)
network
developed,
implications
tumour
mutational
burden
(TMB)
drug
response
examined.
A
comprehensive
bioinformatics
analysis
these
hub
performed,
followed
experimental
through
quantitative
real-time
PCR
(qRT-PCR)
functional
cellular
assays.
showed
high
predictive
accuracy
survival.
GO
GSEA
indicated
that
are
involved
pathways
related
oestrogen
metabolism.
PPI
consisting
201
nodes
568
edges
the
TMB
differed
significantly
between
high-
low-risk
groups.
Analyses
identified
three
CRLRs,
SOS1-IT1,
AC104695.3,
LINC01269,
which
differentially
expressed
HCC
tissues.
In
vitro,
LINC01269
found
enhance
proliferation,
invasion,
migration.
first
systematic
exploration
roles
demonstrates
their
critical
involvement
disease's
pathogenesis
possible
implication.
distinct
expression
patterns
suggest
may
facilitate
targets.
Biomedicines,
Год журнала:
2025,
Номер
13(1), С. 236 - 236
Опубликована: Янв. 20, 2025
Background:
Hepatocellular
carcinoma
(HCC)
is
a
highly
heterogeneous
tumor,
and
distinguishing
its
subtypes
holds
significant
value
for
diagnosis,
treatment,
the
prognosis.
Methods:
Unsupervised
clustering
analysis
was
conducted
to
classify
HCC
subtypes.
Subtype
signature
genes
were
identified
using
LASSO,
SVM,
logistic
regression.
Survival-related
Cox
regression,
their
expression
function
validated
via
qPCR
gene
interference.
GO,
KEGG,
GSVA,
GSEA
used
determine
enriched
signaling
pathways.
ESTIMATE
CIBERSORT
calculate
stromal
score,
tumor
purity,
immune
cell
infiltration.
TIDE
employed
predict
patient
response
immunotherapy.
Finally,
drug
sensitivity
analyzed
oncoPredict
algorithm.
Results:
Two
with
different
profiles
identified,
where
subtype
S1
exhibited
significantly
shorter
survival
time.
A
scoring
formula
nomogram
constructed,
both
of
which
showed
an
excellent
predictive
performance.
COL11A1
ACTL8
as
survival-related
among
genes,
downregulation
could
suppress
invasion
migration
HepG2
cells.
characterized
by
upregulation
pathways
related
collagen
extracellular
matrix,
well
associated
xenobiotic
metabolic
process
fatty
acid
degradation.
higher
scores,
scores
infiltration
macrophages
M0
plasma
cells,
lower
purity
NK
cells
(resting/activated)
resting
mast
S2
more
likely
benefit
from
appeared
be
sensitive
BMS-754807,
JQ1,
Axitinib,
while
SB505124,
Pevonedistat,
Tamoxifen.
Conclusions:
patients
can
classified
into
two
based
on
profiles,
exhibit
distinctions
in
terms
pathways,
microenvironment,
sensitivity.
World Journal of Gastrointestinal Oncology,
Год журнала:
2025,
Номер
17(3)
Опубликована: Фев. 13, 2025
Hepatocellular
carcinoma
remains
a
significant
cause
of
mortality
worldwide,
particularly
among
patients
with
liver
cirrhosis.
In
most
cases,
surveillance
in
cirrhotic
is
neglected,
leading
to
diagnosis
when
the
neoplasm
at
an
advanced
stage.
Within
this
context,
Zhou
et
al
carried
out
network
meta-analysis
demonstrate
effectiveness
hepatic
arterial
infusion
chemotherapy,
concluding
that
it
superior
approach
compared
sorafenib
and
transarterial
chemoembolization
treatment
hepatocellular
carcinoma.
Unfortunately,
question
lacks
methodological
rigor,
preventing
authors
from
making
more
definitive
assertions.
Additionally,
we
understand
chemoembolization,
properly
indicated,
highly
effective
therapeutic
option,
sorafenib,
given
results
new
therapies
based
on
immune
checkpoint
inhibitors,
no
longer
recommended
drug
for
these
patients.
Therefore,
believe
use
chemotherapy
increasingly
limited
strong
scientific
support.
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 17, 2025
Hepatocellular
carcinoma
(HCC)
is
the
most
prevalent
primary
liver
malignancy
and
a
leading
cause
of
cancer-related
deaths
globally.
The
asymptomatic
progression
early-stage
HCC
often
results
in
diagnosis
at
advanced
stages,
significantly
limiting
therapeutic
options
worsening
prognosis.
Immunotherapy,
with
immune
checkpoint
inhibitors
(ICIs)
forefront,
has
revolutionized
treatment.
Nevertheless,
tumor
heterogeneity,
evasion,
presence
immunosuppressive
components
within
microenvironment
(TIME)
continue
to
compromise
its
efficacy.
Furthermore,
resistance
or
non-responsiveness
ICIs
some
patients
underscores
urgent
need
unravel
complexities
TIME
design
innovative
strategies
that
enhance
immunotherapeutic
outcomes.
Emerging
evidence
revealed
pivotal
role
N6-methyladenosine
(m6A),
prominent
RNA
methylation
modification,
shaping
HCC.
By
regulating
stability
translation,
m6A
influences
immune-related
factors,
including
cytokines
molecules.
This
modification
governs
PD-L1
expression,
facilitating
escape
contributing
against
ICIs.
Advances
this
field
have
also
identified
m6A-related
regulators
as
promising
biomarkers
for
predicting
immunotherapy
response
potential
targets
optimizing
treatment
review
examines
regulatory
mechanisms
HCC,
focus
on
impact
cells
cytokine
dynamics.
It
explores
targeting
pathways
improve
efficacy
outlines
emerging
directions
future
research.
These
insights
aim
provide
foundation
developing
novel
overcome
advance
Oncology Letters,
Год журнала:
2025,
Номер
29(4), С. 1 - 14
Опубликована: Март 4, 2025
Hepatocellular
carcinoma
(HCC)
ranks
among
the
most
prevalent
and
lethal
cancers
affecting
humans.
Currently,
there
are
limited
effective
treatments
available
for
HCC.
Carfilzomib,
a
proteasome
inhibitor,
is
known
to
exert
anti-HCC
activities;
however,
its
underlying
mechanisms
of
action
remain
unclear.
In
present
study,
efficacy
carfilzomib
against
HCC
was
evaluated
were
explored.
Cell
Counting
Kit-8,
5-ethynyl-2-deoxyuridine
staining
colony
formation
assays
employed
analyze
antiproliferative
effect
on
MHCC-97H
Huh7
cells.
Additionally,
flow
cytometry
used
assess
cell
cycle
Transwell
evaluate
migration
invasion.
Western
blotting
utilized
examine
protein
expression
levels
associated
with
arrest.
Furthermore,
short
hairpin
RNA
(shRNA)
transfection
investigate
role
DNA
damage
inducible
α
(GADD45α)
carfilzomib-induced
A
xenograft
tumor
model
using
nude
mice
activity
in
vivo.
The
findings
demonstrated
that
inhibited
proliferation,
invasion
both
addition,
caused
arrest
by
suppressing
cyclin
A2,
E1
cyclin-dependent
kinases
2
4.
Carfilzomib
also
upregulated
GADD45α,
activated
MAPK
pathway
GADD45α
through
shRNA
abolished
growth
To
conclude,
research
revealed
inhibits
progression
cells
upregulating
expression,
suggesting
could
be
potential
chemotherapeutic
agent
Frontiers in Oncology,
Год журнала:
2025,
Номер
15
Опубликована: Март 28, 2025
Liver
cancer,
characterized
by
its
insidious
nature,
aggressive
invasiveness,
and
propensity
for
metastasis,
has
witnessed
a
sustained
increase
in
both
incidence
mortality
rates
recent
years,
underscoring
the
urgent
need
innovative
diagnostic
therapeutic
approaches.
Emerging
research
indicates
that
CircRNAs
(circular
RNAs)
are
abundantly
stably
present
within
cells,
with
their
expression
levels
closely
associated
progression
of
various
malignancies,
including
hepatocellular
carcinoma.
In
context
liver
cancer
progression,
circRNAs
exhibit
promising
potential
as
highly
sensitive
biomarkers,
offering
novel
avenues
early
detection,
also
function
pivotal
regulatory
factors
carcinogenic
process.
This
study
endeavors
to
elucidate
biogenesis,
functional
roles,
underlying
mechanisms
carcinoma,
thereby
providing
fresh
perspective
on
pathogenesis
laying
robust
foundation
development
more
precise
effective
tools
strategies.
Biomarker Research,
Год журнала:
2025,
Номер
13(1)
Опубликована: Март 4, 2025
Hepatocellular
carcinoma
(HCC)
can
be
classified
into
several
subtypes
based
on
molecular
traits,
aiding
in
prognostic
stratification.
The
subtype
with
a
poor
prognosis
is
often
associated
stem/progenitor
features.
This
study
focused
identifying
circulating
biomarkers
for
aggressive
HCC.
We
searched
secretory
proteins
whose
expression
was
positively
the
markers
KRT19,
EPCAM,
and
PROM1
2
independent
HCC
cohorts.
Serum
folate
receptor
1
(FOLR1)
levels
were
measured
238
chronic
liver
disease
247
patients,
evaluating
their
diagnostic
capabilities.
FOLR1
identified
as
protein
that
correlated
all
3
both
discovery
validation
Higher
detected
tumor
than
nontumor
tissues
subtypes,
activation
of
p53,
DNA
repair,
Myc,
E2F,
PI3K/AKT/mTOR
pathways.
tumoral
patients
significantly
elevated
compared
those
hepatitis
or
nonliver
disease.
demonstrated
performance
comparable
to
alpha-fetoprotein
(AFP),
combination
increased
accuracy.
Elevated
serum
regardless
treatment,
especially
early-stage
multivariate
analysis
revealed
level
Gender,
Age,
AFP-L3,
AFP,
Des-gamma-carboxy
prothrombin
(GALAD)
score
predictors
further
stratifying
prognosis.
stemness-associated
biomarker
HCC,
serving
marker
indicator
